To address the limitations of previous studies and determine accurately the relationship between TP53 mutation and HGPSC, we designed pilot and validation studies to measure the mutation frequency in a homogeneous group of advanced stage HGPSC cancers from a large population-based cohort. The gene discussed is TP53; the disease is cancer.